Medindia LOGIN REGISTER
Medindia
Advertisement

PierianDx Expands to Australia with Addition of Anatomical Pathology PathWest Laboratory Medicine

Tuesday, June 12, 2018 Drug News
Advertisement
Western Australia's leading referral pathology laboratory adopts PierianDx solution to provide precision oncology to patients in Australia.

ST. LOUIS, June 12, 2018 /PRNewswire-PRWeb/ -- PierianDx, the leading clinical genomics technology company that enables precision medicine, announced today that the Department of Anatomical Pathology PathWest Laboratory Medicine will use the company's Clinical Genomics WorkSpace™ (CGW) platform, the industry's leading integrated workspace for clinical genomic analytics, classification, interpretation and reporting. Pathwest, the first in Australia to use the Illumina TruSight Tumor 170 (TST170) panel, will use CGW to provide clinical insight to the large amount of data generated from the interrogation of 170 cancer genes.
Advertisement

PathWest is the pathology laboratory of the Western Australia Ministry of Health that presides over 50 hospitals spread across an area of 2.5 million square kilometers, providing world class healthcare to 2.5 million people.
Advertisement

"We look forward to sharing our expertise with PathWest as they advance their NGS testing operations to provide clinical insights from the Illumina TST170 panel," said Michael Sanderson, CEO at PierianDx. "Our partnership will help pave the way for greater adoption of NGS testing throughout all of Australia."

By partnering with PierianDx to offer a comprehensive solution for precision oncology, PathWest will gain genomic and clinical insights from powerful NGS testing, thereby delivering on the power of precision medicine to Western Australia cancer patients.

"PierianDx's technology combined with our scientific capabilities will accelerate PathWest's ability to provide enhanced, clinically actionable information and expand our NGS test offerings," said Clinical Professor, Benhur Amanuel, Service Director of Anatomical Pathology, PathWest Laboratory Medicine.

About PierianDx Every year millions of people bet their lives on precision medicine. PierianDx is on a mission to make sure that bet pays off. At PierianDx we empower progressive health institutions and diagnostic laboratories to build world-class precision medicine programs. Our industry-leading clinical genomics technologies and expertise deliver the most integrated, trusted, and collaborative approach across the clinical care spectrum. From genomic sequencing and biomedical informatics in the laboratory to reporting and decision support at the patient's bedside, we drive the adoption of genomics in clinical care and accelerate the fight against cancer and other diseases.

About PathWest PathWest Laboratory Medicine WA is committed to providing excellence and innovation in pathology testing, teaching and research, positively contributing to the health and wellbeing of the community. PathWest has a proud service record as the pathology arm of the Western Australian Government and as Western Australia's leading referral pathology laboratory and responds to the needs of virtually every medical practitioner in the State. PathWest offers a round-the-clock commitment to the health needs of the entire Western Australian community through 24 hour laboratory facilities, results lines and on call clinicians. Supporting this is a network of 6 major teaching hospitals, 44 metro and regional hospitals, 21 laboratories and the convenience of over 25 specimen collection centres spread across the State from Esperance in the south through to as far north as Kununurra, making PathWest's services accessible to everyone. For more information visit http://www.pathwest.health.wa.gov.au.

 

SOURCE PierianDx Inc

Sponsored Post and Backlink Submission


Latest Press Release on Drug News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close